Main Article Content
Eclampsia: A Randomized Double Blind Trial of Magnesium Sulphate and Diazepam in Lagos, Nigeria
Abstract
Background: Magnesium sulphate is used widely to prevent eclamptic seizure in pregnant women with Hypertension but few studies have compared the efficacy of magnesium sulphate with that of other drugs in Nigeria.
Objective: This randomnized study is to compare the efficacy of magnesium sulphate with that of diazepam in preventing seizures in hypertensive women during labour.
Methods: Eclamptic patients were randomly assigned to receive either magnesium sulphate or diazepam. The magnesium sulphate regimen used was as described by Zuspan. The diazepam regimen was a loading dose of 10mg intravenously over two minutes and repeated when convulsions recurred.
Primary measure of outcome: Recurrence of convulsions and maternal death.
Results: The use of magnesium sulphate was found to be significantly associated with less serious morbidity in terms of recurrence of convulsions (P = 0.0047), respiratory, and renal complications (P = 0.004) and improvement in level of unconsciousness (P = 0.0024) in comparison to diazepam use. Eight maternal deaths occurred, seven (87.5%) in unbooked/ predelivery patients. More vaginal delivery and less operative delivery were recorded in the magnesium group as compared to the diazepam group (P = 0.039). Low Apgar scores < 7 at 1min were twice as common in the diazepam group as compared to the magnesium sulphate group (P = 0.04). There were four early neonatal deaths in the diazepam group and none in the magnesium sulphate group.
Conclusion: This study has produced support for the touted advantages of magnesium sulphate over diazepam for the mother and the infant in the treatment of eclampsia.
Key Words: Eclampsia, Recurrent Convulsions, Magnesium sulphate,Diazepam
[Trop J Obstet Gynaecol, 2004; 21:143-147]
Objective: This randomnized study is to compare the efficacy of magnesium sulphate with that of diazepam in preventing seizures in hypertensive women during labour.
Methods: Eclamptic patients were randomly assigned to receive either magnesium sulphate or diazepam. The magnesium sulphate regimen used was as described by Zuspan. The diazepam regimen was a loading dose of 10mg intravenously over two minutes and repeated when convulsions recurred.
Primary measure of outcome: Recurrence of convulsions and maternal death.
Results: The use of magnesium sulphate was found to be significantly associated with less serious morbidity in terms of recurrence of convulsions (P = 0.0047), respiratory, and renal complications (P = 0.004) and improvement in level of unconsciousness (P = 0.0024) in comparison to diazepam use. Eight maternal deaths occurred, seven (87.5%) in unbooked/ predelivery patients. More vaginal delivery and less operative delivery were recorded in the magnesium group as compared to the diazepam group (P = 0.039). Low Apgar scores < 7 at 1min were twice as common in the diazepam group as compared to the magnesium sulphate group (P = 0.04). There were four early neonatal deaths in the diazepam group and none in the magnesium sulphate group.
Conclusion: This study has produced support for the touted advantages of magnesium sulphate over diazepam for the mother and the infant in the treatment of eclampsia.
Key Words: Eclampsia, Recurrent Convulsions, Magnesium sulphate,Diazepam
[Trop J Obstet Gynaecol, 2004; 21:143-147]